Latest news in cancer
How Targeted Therapy is Revolutionizing Advanced Cancer Treatment?
In the field of oncology, the emergence of targeted therapy has revolutionized the treatment landscape for advanced cancers. Unlike conventional chemotherapy,...
Utilizing Immunotherapy to Treat Late-Stage Cancers
Introduction Immunotherapy has become a groundbreaking method in cancer treatment, especially for advanced-stage cancer treatments that have...
Survivorship and long-term care in advanced cancers
Dive into the complexities of survivorship and long-term care for individuals facing advanced cancers. Discover the latest advancements in care coordination...
FasTCAR-T GC012F demonstrated overall 100% response rate in newly diagnosed multiple myeloma
Introduction Even in transplant-eligible (TE) patients, typical first-line treatments for high-risk (HR) newly-diagnosed multiple myeloma (NDMM) have dismal...
CAR T Cell therapy for AIDS related B-Cell malignancies
CAR T cell therapy for HIV-related B cell malignancies involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs)...
Cancer statistics in India 2024: Incidence, estimates and projections
In 2024, cancer will remain a significant health challenge in India. The country sees over 1.5 million new cases a year. Breast and oral cancers are most...
India declared cancer capital of the world – Apollo report
India declared cancer capital of the world India was designated as the “cancer capital of the world” in the 4th edition of Apollo Hospitals’...
Mirvetuximab soravtansine-gynx is approved by the USFDA for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be...
Ponatinib with chemotherapy has received accelerated approval by the USFDA for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination...
Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma
March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug...
Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin...
Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia
6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.